Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McConnell

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Journal of Medicinal Chemistry|August 5, 2024
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid TumorsJames C Tarr, James M Salovich, Martin Aichinger, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimenSimon J F Macdonald, Keith G Watson, Rachel Cameron, et al.
Journal of Medicinal Chemistry|April 15, 2005
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenzaSimon J F Macdonald, Rachel Cameron, Derek A Demaine, et al.
Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Nature Chemical Biology|June 11, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Nature Chemical Biology|July 4, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2019
Drugging an undruggable pocket on KRASDirk Kessler, Michael Gmachl, Andreas Mantoulidis, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Journal of Medicinal Chemistry|August 5, 2024
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid TumorsJames C Tarr, James M Salovich, Martin Aichinger, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimenSimon J F Macdonald, Keith G Watson, Rachel Cameron, et al.
Journal of Medicinal Chemistry|April 15, 2005
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenzaSimon J F Macdonald, Rachel Cameron, Derek A Demaine, et al.
Journal of Medicinal Chemistry|March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJuergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Journal of Medicinal Chemistry|November 6, 2019
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase InhibitorsHarald Engelhardt, Dietrich Böse, Mark Petronczki, et al.
Nature Chemical Biology|June 11, 2019
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Nature Chemical Biology|July 4, 2019
Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC designWilliam Farnaby, Manfred Koegl, Michael J Roy, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2019
Drugging an undruggable pocket on KRASDirk Kessler, Michael Gmachl, Andreas Mantoulidis, et al.
Pageof 24